Publication:

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

Loading...
Thumbnail Image

Open/View Files

Date

2018

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley and Sons Inc.
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Jurmeister, S., A. Ramos‐Montoya, C. Sandi, N. Pértega‐Gomes, K. Wadhwa, A. D. Lamb, M. J. Dunning, et al. 2018. “Identification of potential therapeutic targets in prostate cancer through a cross‐species approach.” EMBO Molecular Medicine 10 (3): e8274. doi:10.15252/emmm.201708274. http://dx.doi.org/10.15252/emmm.201708274.

Abstract

Abstract Genetically engineered mouse models of cancer can be used to filter genome‐wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB‐Cre/PtenloxP/loxP and p53loxP/lox PRbloxP/loxP, and integrated this with published human prostate cancer expression data to pinpoint cancer‐associated gene expression changes that are conserved between the two species. To identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we revealed a functional role for the kinase MELK as a driver and potential therapeutic target in prostate cancer. We found that MELK expression was required for cell survival, affected the expression of genes associated with prostate cancer progression and was associated with biochemical recurrence.

Description

Research Data

Keywords

cross‐species analysis, , mouse models, new cancer targets, prostate cancer, Cancer, Chromatin, Epigenetics, Genomics & Functional Genomics, Urogenital System

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories